Patents
US 12714691 B2: Method of treating triple-negative breast cancer
- Granted
- 2026-08-25
- Filed
- 2019-02-08 application 16967472
- Type
- Utility · 20 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
The disclosure provides a method of treating triple negative breast cancer in a patient, comprising administering a therapeutically effective amount of a compound selected from oxyphenisatin, oxyphenisatin acetate, and bisacodyl, or the pharmaceutically acceptable salts or hydrates of any of the foregoing to the patient. The disclosure also provides methods of using oxyphenisatin or bisacodyl, or a salt or hydrate thereof, as a first active agent in combination with one or more additional active agents to treat triple negative breast cancer. The disclosure further provides methods for determining whether a patient suffering from triple negative breast cancer would be responsive to treatment with oxyphenisatin or bisacodyl.
Source: PTBLXML, file of 2026-08-25 (ipgb20260825.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| The United States of America, as represented by the Secretary, Department of Health and Human Services | US federal government | Bethesda, MD | PTBLXML, file of 2026-08-25 | |
| Genome Research Limited 16 patents | Foreign company or organization | London, GB | GENOME RESEARCH LLC State business registration FUZZY low confidence: same name (legal endings aside), one of each nationally | PTBLXML, file of 2026-08-25 |
| Dana Farber Cancer Institute 892 patents | US company or organization | Boston, MA | DANA-FARBER CANCER INSTITUTE, INC. Federal lobbying client EXACT high confidence: identical full name and state DANA-FARBER CANCER INSTITUTE Nonprofit FUZZY medium confidence: same name (governing-board words and legal endings aside) and state | PTBLXML, file of 2026-08-25 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| William Curtis Reinhold | Rockville, MD | PTBLXML, file of 2026-08-25 | ||
| Mathew Garnett | Cambridge, GB | PTBLXML, file of 2026-08-25 | ||
| Vinodh Nalin Rajapakse | Rockville, MD | PTBLXML, file of 2026-08-25 | ||
| Yves Pommier | Bethesda, MD | PTBLXML, file of 2026-08-25 | ||
| Augustin Luna | Brookline, MA | PTBLXML, file of 2026-08-25 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| A61K | Preparations for medical, dental or toiletry purposes | A61K31/404 | PTBLXML, file of 2026-08-25 |
| A61N | Electrotherapy; magnetotherapy; radiation therapy; ultrasound therapy | A61N5/10 | PTBLXML, file of 2026-08-25 |
| A61P | Specific therapeutic activity of chemical compounds or medicinal preparations | A61P35/00 | PTBLXML, file of 2026-08-25 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
No recorded assignments or security interests on file for this patent.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.